News

Wave Life’s WVE-004 Shows Proof of Concept in Cell, Mouse Models

WVE-004, Wave Life Sciences‘ experimental therapy for people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, has demonstrated proof-of-concept efficacy in cell and animal models, a new study shows. The nucleic acid-based therapy was able to “potently” reduce the toxic RNA molecules and small proteins…

ALS Association Offers Exploratory Grant Opportunities

The ALS Association is calling for applications for a new Seed Grant Program designed to support exploratory amyotrophic lateral sclerosis (ALS) research. The one-year grants of up to $50,000 each will fund investigations that could have a significant impact on the progressive neurodegenerative disorder. Specifically, funded projects…